D-dimer and lower limb ultrasound as prognostic factors for recurrent deep venous thrombosis and pulmonary embolism: A systematic review and meta-analysis
Clinical Snapshot
PICO Framework
| P — Population | Patients with venous thromboembolism (deep vein thrombosis and/or pulmonary embolism) who have completed anticoagulation therapy |
| I — Intervention | D-dimer testing and/or lower limb ultrasonography assessment |
| C — Comparator | Normal D-dimer levels and/or absence of residual vein thrombosis |
| O — Outcomes | Recurrent venous thromboembolism events |
Bottom Line
This systematic review examined D-dimer and lower limb ultrasound as prognostic tools for VTE recurrence after anticoagulation cessation. While both residual vein thrombosis (OR 2.00) and positive D-dimer (OR 2.48) showed statistically significant associations with recurrence, the evidence quality is very low with substantial heterogeneity. The high I² values (85.7% for ultrasound, 56.0% for D-dimer) and wide prediction intervals indicate inconsistent results across studies, limiting clinical utility. These biomarkers should not be used as isolated decision-making tools for anticoagulation duration. The findings support existing guidelines that emphasize individualized risk assessment incorporating multiple clinical factors rather than relying on single prognostic markers. Clinicians should interpret these tests cautiously within broader clinical context when making anticoagulation decisions.
Key Findings
P Value: Not reported in abstract
Effect Size: OR 2.00 for residual vein thrombosis; OR 2.48 for positive D-dimer
Primary Outcome: Recurrent venous thromboembolism
Nnt Or Sensitivity: Two-fold increased risk for RVT; 2.48-fold increased risk for positive D-dimer
Confidence Interval: RVT: 95% CI 1.02-3.94; D-dimer: 95% CI 1.85-3.33
Clinical Application
Both tests readily available in Australian healthcare system D-dimer and ultrasound widely accessible through Medicare; relevant to TGA-approved anticoagulants and RACGP VTE management guidelines Patients with completed VTE treatment considering anticoagulation duration
Abstract
Venous thromboembolic disease is a chronic, recurrent condition. The optimal duration of anticoagulation therapy remains uncertain. We aim to evaluate D-dimer and lower limb ultrasonography as prognostic tools for the recurrence of venous thromboembolism. A search was conducted on May 28, 2022, in the Medline, Embase, and Cochrane databases. Inclusion criteria encompassed cohort studies, case-control studies, and clinical trials. Two reviewers independently screened all records and analyzed studies for inclusion/exclusion criteria, as well as risk of bias, using a structured framework (PROSPERO ID: CRD42022341082). The initial search yielded 4652 titles and abstracts. After removing 777 duplicates and reviewing 3875 titles and abstracts, 48 articles providing information on D-dimer and/or lower limb ultrasonography as prognostic factors were finally included. Very low-certainty evidence suggests that both residual vein thrombosis (RVT) at anticoagulation discontinuation and a positive post-treatment D-dimer are significantly associated with an increased risk of recurrent venous thromboembolism (VTE). For RVT, the pooled analysis showed a two-fold increase in risk (OR 2.00, 95% CI 1.02 to 3.94; I² = 85.7) while for positive D-dimer, the risk was similarly elevated (OR, 2.48; 95% CI, 1.85-3.33; I² = 56.0). In conclusion, very low-quality evidence suggests that abnormal D-dimer and RVT are associated with recurrent VTE; however, this association is inconsistent due to significant heterogeneity and wide prediction intervals. These biomarkers should be interpreted with caution as isolated predictors in clinical practice.
References
- 1.Salinas-Mendoza, S., Burgos Cárdenas, Á. J., & Rhenals, S. D. M. M. (2024). D-dimer and lower limb ultrasound as prognostic factors for recurrent deep venous thrombosis and pulmonary embolism: A systematic review and meta-analysis. PLoS One. https://doi.org/10.1371/journal.pone.0340158
Related Research
Human vaccines & immunotherapeutics
Artificial intelligence in immune checkpoint inhibitor research: A bibliometric analysis of the landscape
30 July 2026
Blood advances
Successful gene therapy for transfusion-dependent α-thalassemia: a case report
29 July 2026
Journal of chemical information and modeling
Functionally Guided Graph Learning for Robust Cross-Patient Cell-Type Annotation in Single-Cell RNA Sequencing
29 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service